Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics to Acquire CRO Neurofit for $1.7M; CNS Tx Development Planned

NEW YORK, Dec. 17 (GenomeWeb) - Bionomics will acquire Neurofit, a French contract research organization, in a €1.25 million ($1.65 million) cash-and-stock transaction expected to close before March 1, the Adelaide, Australia-based company said today.

 

Bionomics will pay €1 million in cash and € 250,000 in shares for Strasbourg, France-based Neurofit. The company conducts preclinical testing of developmental therapeutics for CNS disorders using cellular and animal models, and lists Novartis, Serono, Boehringer-Ingelheim, and Biogen as clients.

 

The acquisition will enhace Bionomics' therapeutic development capacity for CNS disorders, Bionomics said.

 

Additionally, the acquisition includes intellectual property rights to an animal model of Parkinson's Disease, developed by Institute Pasteur, and other animal models.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.